Conversion from tacrolimus to belatacept improves renal function in kidney transplant patients with chronic vascular lesions in allograft biops

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Pérez-Sáez, María José
• dc.contributor.author Yu, Bryant
• dc.contributor.author Uffing, Audrey
• dc.contributor.author Murakami, Naoka
• dc.contributor.author Borges, Thiago J.
• dc.contributor.author Azzi, Jamil
• dc.contributor.author El Haji, Sandra
• dc.contributor.author Gabardi, Steve
• dc.contributor.author Riella, Leonardo V.
• dc.date.accessioned 2019-11-27T08:32:50Z
• dc.date.available 2019-11-27T08:32:50Z
• dc.date.issued 2018
• dc.description.abstract BACKGROUND: Conversion from tacrolimus to belatacept has been shown to be beneficial for an increasing number of kidney transplant (KT) patients. Predicting factors for favorable outcomes are still unknown. We aimed to investigate whether histological vascular lesions at the time of conversion might correlate with greater improvement in renal function post-conversion. METHODS: The study was conducted on a retrospective cohort of 34 KT patients converted from tacrolimus to belatacept. All patients underwent an allograft biopsy prior to conversion. We analyzed the evolution of the estimated glomerular filtration rate (eGFR) at 3 and 12 months after conversion. RESULTS: Median time to conversion was 6 (2-37.2) months post-transplant. About 52.9% of patients had moderate-to-severe chronic vascular lesions (cv2-3). We observed an increase in eGFR in the whole cohort from 35.4 to 41 mL/min/1.73 m2 at 3 months (P = 0.032) and 43.7 at 12 months (P = 0.013). Nine patients experienced acute rejection post-conversion, with one graft loss observed beyond the first year after conversion. Patients with cv2-3 had significant improvement in eGFR at 12 months (+8.6 mL/min/1.73 m2; 31.6 to 40.2 mL/min/1.73 m2; P = 0.047) compared with those without these lesions (+6.8 mL/min/1.73 m2; 40.9 to 47.7 mL/min/1.73 m2; P = 0.148). CONCLUSIONS: Conversion from tacrolimus to belatacept has a beneficial effect in terms of renal function in KT patients. This benefit might be more significant in patients with cv in the biopsy.
• dc.format.mimetype application/pdf
• dc.identifier.citation Pérez-Sáez MJ, Yu B, Uffing A, Murakami N, Borges TJ, Azzi J et al. Conversion from tacrolimus to belatacept improves renal function in kidney transplant patients with chronic vascular lesions in allograft biopsy. Clin Kidney J. 2018 Dec 1;12(4):586-91. DOI: 10.1093/ckj/sfy115
• dc.identifier.doi http://dx.doi.org/10.1093/ckj/sfy115
• dc.identifier.issn 2048-8505
• dc.identifier.uri http://hdl.handle.net/10230/42999
• dc.language.iso eng
• dc.publisher Oxford University Press
• dc.relation.ispartof Clinical Kidney Journal. 2018 Dec 1;12(4):586-91
• dc.rights Copyright © The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by-nc/4.0/
• dc.subject.keyword Creatinine clearance
• dc.subject.keyword Immunosuppression
• dc.subject.keyword Kidney transplantation
• dc.subject.keyword Renal biopsy
• dc.subject.keyword Tacrolimus
• dc.title Conversion from tacrolimus to belatacept improves renal function in kidney transplant patients with chronic vascular lesions in allograft biops
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion